Bausch Health Companies (BHC) Expected to Announce Earnings on Thursday

Bausch Health Companies (NYSE:BHC - Get Free Report) is expected to be announcing its earnings results before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of $1.12 per share for the quarter. Bausch Health Companies has set its FY 2025 guidance at EPS.Investors that are interested in participating in the company's conference call can do so using this link.

Bausch Health Companies (NYSE:BHC - Get Free Report) last issued its quarterly earnings data on Wednesday, February 19th. The company reported $1.21 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.65 by ($0.44). Bausch Health Companies had a negative return on equity of 650.39% and a negative net margin of 0.48%. The business had revenue of $2.56 billion during the quarter, compared to the consensus estimate of $2.51 billion. On average, analysts expect Bausch Health Companies to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Bausch Health Companies Trading Up 1.7 %

BHC traded up $0.13 during trading hours on Friday, hitting $7.31. The company's stock had a trading volume of 3,004,609 shares, compared to its average volume of 3,096,627. The company has a 50-day simple moving average of $7.35 and a 200 day simple moving average of $7.48. The firm has a market capitalization of $2.64 billion, a PE ratio of -60.87, a PEG ratio of 0.38 and a beta of 0.68. Bausch Health Companies has a fifty-two week low of $3.96 and a fifty-two week high of $11.46.

Analysts Set New Price Targets

A number of research analysts have recently commented on BHC shares. StockNews.com raised Bausch Health Companies from a "hold" rating to a "buy" rating in a report on Friday, October 25th. Jefferies Financial Group restated a "hold" rating and set a $8.00 price target (down from $12.00) on shares of Bausch Health Companies in a research report on Thursday, February 6th. Finally, Royal Bank of Canada reduced their price target on shares of Bausch Health Companies from $11.00 to $10.00 and set a "sector perform" rating for the company in a research note on Thursday, January 30th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and one has given a buy rating to the company. According to MarketBeat.com, the company has an average rating of "Hold" and an average price target of $7.42.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.